Biotech Values

[DewDiligence]

ENTA announces early-stage programs in HBV/RSV—phase-1 for EDP-494 (HCV cyclophilin inhibitor) has started:

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-r-d-130000306.html

Enanta Pharmaceuticals…announced today that it has expanded its research and development programs within the company’s core focus areas of virology and liver disease to include new programs to treat hepatitis B virus (HBV) and respiratory syncytial virus (RSV) infections.

…Significant progress has been made in discovering, characterizing, and seeking patent protection for new core inhibitors for HBV and new non-fusion inhibitors for RSV. Enanta expects to initiate phase 1 clinical development in at least one of the new programs in 2017.

…Enanta also announced that the first subject was dosed in a phase 1 clinical study with EDP-494, its cyclophilin inhibitor for the treatment of hepatitis C virus (HCV)… Enanta anticipates that cyclophilin inhibitors may be combined with direct-acting antivirals (such as nucleot(s)ide inhibitors of the NS5B HCV target) to provide highly effective new combination treatments for HCV.

More details on the above will be furnished during ENTA’s webcast at JPM Wednesday at 2pm ET and in the breakout (Q&A) session at 2:30pm ET.